You are here

News

July 15, 2015
Host Genetics Played a Role in RV144 Protection

Researchers at the U.S. Military HIV Research Program (MHRP) tested whether specific variants of immune response genes called HLA were associated with greater protection against the virus. 

“We found that antibody responses correlated with increased or decreased risk of acquiring HIV only in the presence of specific host HLA alleles,” said senior author Dr. Rasmi Thomas.  By identifying...

June 3, 2015
Humanized DRAG Mouse Model Holds Promise For Pre-Clinical Testing of Candidate HIV Vaccines

A new study led by MHRP researchers in collaboration with the Military Malaria Vaccine Program shows that T follicular helper cells (Tfh) accumulate in the gut and female reproductive tract of humanized DRAG mice, which are highly permissive to HIV infection. Researchers believe this will provide a new pre-clinical model to understand the early events in mucosal HIV infection and help to...

May 18, 2015
MHRP Marks HIV Vaccine Awareness Day

The 2014 Ebola outbreak in West Africa is a stark reminder of the constant threat infectious diseases pose to communities around the world, including  the U.S. Military. If we’d had an effective vaccine against Ebola, much of the pain, suffering and death could have been avoided. 

This experience serves as a reminder of the power of vaccines, which have dramatically reduced the impact...

April 22, 2015
Long-term Adverse Health Effects of Ebola Survivors Examined in New Lancet ID Paper

Survivors of the 2007-08 Bundibugyo ebolavirus (BDBV) outbreak in Uganda experienced negative health effects that persisted more than two years after the outbreak claimed 39 lives, according to findings from an MHRP study published in The Lancet Infectious Diseases today. 

The study represents the largest long-term study to-date on Ebola survivors, and examines health events more than...

April 20, 2015
MHRP Researchers Provide Insight into Worlds Most Potent Vaccine Adjuvant

In a new paper titled, “Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate,” MHRP researcher and liposome pioneer Dr. Carl Alving and his team deconstruct the underlying science behind the physical structure of the world’s most potent vaccine adjuvant. 

The paper, published in the March issue of the journal, BBA...

April 1, 2015
Findings from WRAIR-NIAID EBOV Clinical Trial Published in NEJM

Findings from a WRAIR/NIAID led Ebola vaccine clinical trail were published in the New England Journal of Medicine today, highlighting that the vaccine candidate is safe and elicits a robust immune response.  The VSV-EBOV candidate was tested in a small phase 1 clinical trial that explored the safety and immunogeniticy of the vaccine when administered at different doses. MHRP's Diagnostics...

March 18, 2015
MHRP and Colleagues Featured in Special JAIDS Supplement

MHRP's Global Health Programs (GHP) collaborated on a special supplement to the latest edition of the Journal of Acquired Immune Deficiency Syndromes (JAIDS). This special issue features literature reviews that examines the impact of HIV care and treatment interventions in low- and middle-income countries. It was supported by U.S. President's Emergency Plan for AIDS Relief. GHP's Director Dr....

February 26, 2015
Bioethics Commission Urges US to Adopt Ethical Approach to Ebola & Health Preparedness

Today, the Presidential Commission for the Study of Bioethical Issues (Bioethics Commission) argued that the federal government has both a prudential and a moral responsibility to actively participate in coordinated global responses to public health emergencies wherever they arise.The report, "Ethics and Ebola: Public Health Planning and Reponse," details findings and recommendations from the...

February 20, 2015
Building on RV144: HIV Vaccine Trial Launches in South Africa

A clinical trial called HVTN 100 has been launched in South Africa to study an investigational HIV vaccine regimen for safety and the immune responses it generates in study participants. This experimental vaccine regimen is based on the one tested in the U.S. Military HIV Research Program-led RV144 clinical trial in Thailand—the first study to demonstrate that a vaccine can protect people from...

February 6, 2015
New Cohort Study Begins in Mozambique

MHRP recently began a new cohort study, RV363, to assess the incidence of HIV and the willingness of adults to participate in future HIV vaccine trials in Mozambique. The study will determine incidence in men and women aged 18–35 in both Maputo and Beira. 

The retention rate of the enrolled cohort will be assessed over a 2-year follow-up period with a quarterly follow-up visit. RV363...

Pages